MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
CertaraJuly 8, 2025
Accelerating Oncology Drug FDA RTOR Submission with Project Management Services
Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…
CertaraJuly 2, 2025
Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction
See how ALBI‑based PopPK modelling supports practical voriconazole dose reductions in liver dysfunction using Phoenix…
CertaraJuly 2, 2025
Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions
Learn how fed‑condition crossover study confirms lurasidone bioequivalence and comparable safety using Phoenix WinNonlin.
CertaraJuly 1, 2025
Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study
Find out how PopPK modelling shows body weight is the key driver of MPA exposure…
CertaraJuly 1, 2025
How Model-informed drug development rescue projects from a risky situation
Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…
CertaraJune 26, 2025
In Vivo PK-PD and Drug-Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia
Explore how dorzagliatin increases exposure and improves antitumor efficacy when combined with PI3Kα inhibitors, analysed…
CertaraJune 19, 2025
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara
Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…
CertaraJune 18, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…
CertaraJune 8, 2025
